RecruitingPediatric AsthmaCritical Illness
Azithromycin for Critical Asthma - Pediatrics
Eligible age
3–17 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Sponsor: Johns Hopkins All Children's Hospital
You may qualify if…
- ✓ Age 3-17 years
- ✓ Admission to the PICU
- ✓ Primary diagnosis of critical asthma
- ✓ Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
- ✓ Prescription for intravenous systemic corticosteroids
You may not qualify if…
- ✕ Critical Congenital Heart Disease Unrepaired
- ✕ Tracheostomy Dependence at Admission
- ✕ Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
- ✕ Past Medical History of Prolonged QT Syndrome or Arrhythmias
- ✕ Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension
Where it's recruiting
Florida
St. Petersburg
Source: ClinicalTrials.gov · NCT06223828 · last updated 2026-08-11